Now enrolling an X-linked CGD clinical trial

The purpose of this study is to find out if EN‑374, an investigational product, is safe and effective in treating people with X‑linked chronic granulomatous disease (X‑CGD).

Now enrolling an X-linked CGD clinical trial

The purpose of this study is to find out if 

EN-374, an investigational product, is safe and effective in treating people with X-linked chronic granulomatous disease (X-CGD).

Now enrolling an X-linked CGD clinical trial

The purpose of this study is to find out if
EN-374, an investigational product, is safe and effective in treating people with X-linked chronic granulomatous disease (X-CGD).

Key Study Elegibility Requirements

  • Male, 18 years or older

  • Diagnosed with X-Linked CGD

  • Have not received a bone marrow transplant or gene therapy treatment

  • There are additional requirements that will be shared if you are interested in learning more
See if You May Qualify >>
See if You May Qualify >>

About EN-374

About EN-374 

  • EN-374 is a gene therapy that works by adding a functioning copy of the CYBB gene directly into the body.


  • EN-374 is being developed by Ensoma, a biotechnology company.
See if You May Qualify >>
Alzheimer's Clinical Trial Patient with Physican

Clinical Trial Locations

Multiple clinical trial sites are being opened across the US. If you are interested in learning more or participating, please speak with your physician or reach out to one of the investigators listed below and on clnicaltrials.gov, study identifier NCT06876363.

Now Open for Enrollment

University of Minnesota

Minneapolis, Minnesota, United States, 55454


Contact:

Alli Travis, BSN, RN, BMTCN

612-625-6150

atravis@umn.edu

Principal Investigator:

Christen Ebens, MD, MPH


Opening Soon:

Additional trial locations opening soon in the US--check back for updates